What We Do


NVP is advancing a new generation and targeted nanoparticle based ADC technology (based around the core and highly accomodating NanoMod™ vehicle) that may provide a vast improvement in flexibility and choice for patients restricted by current treatment options. Both by repositioning existing therapies as well as optimising the delivery of emerging candidates.

Our current candidate focus is oncology, initially pediatric focused, but it is already clear that the technology can be clearly applied to other oncology challenges as well as areas such as imaging, vaccines, and other non-oncological sectors as resources and opportunities present.

Our Technology

NVP is using NanoMod™ as a base entity to obtain an advanced, nanoparticle based, ADC approach able to significantly reposition and enhance existing cancer therapies.

This is because NanoMod™ provides a unique new nanoparticle encapsulated platform designed to harness and enable vastly superior targeting to tumor and other specific cell surface antigens. Also, unlike other targeted technologies, the ‘payload’ for NanoMod™ can be more easily user selected, including proven cytotoxics, nucleic acid based entities or small molecules, or even any mixture thereof. NanoMod™ technology is subject to broad patent control by NVP.

NanoMod™ may serve as an important new, effective and safe drug delivery platform to initially treat both Ewing sarcoma and human adult leukemia as well as other CD99/CD19 based tumors, via our own in-house candidates and beyond via collaborative programs. Logically the technology is widely applicable to other malignancies and therapeutic or even diagnostic opportunities as further candidate options develop.

Why is NanoMod™ unique?


We already have excellent chemotherapeutic compounds and rich knowledge in their everyday use, plus emerging tumor-specific biologicals. However, the key issues that our approach can clearly address include:


– Improving both efficacy and capability of existing agents in existing settings

– Improving applicability of existing drugs to ‘new cancers’

– Improving management of toxicity

– Improving scheduling practicalities with treatments

– Developing innovative or enhanced methods of delivering potential new entities or treatments either in oncology and other therapeutic areas